News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Seattle Genetics, Inc. (SGEN) And Takeda Pharmaceutical Co. Ltd. (TKPYY) Highlight Long-term Follow-up Data from ADCETRIS┬« (Brentuximab Vedotin) Pivotal Clinical Trials In Relapsed Or Refractory Hodgkin Lymphoma And Systemic Anaplastic Large Cell Lymphoma At American Society of Hematology 2013


12/9/2013 9:39:08 AM

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

Seattle Genetics, Inc. (Nasdaq: SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced updated overall survival data from two ADCETRIS (brentuximab vedotin) pivotal Phase 2 clinical trials in relapsed/refractory Hodgkin lymphoma (R/R HL) and relapsed/refractory systemic anaplastic large cell lymphoma (R/R sALCL) were presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in New Orleans, LA, December 7-10, 2013.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES